North America Human Albumin Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The North America Human Albumin Market size is expected to reach US$ 3,246.0 Million by 2031 from US$ 2,244.6 Million in 2024. The market is estimated to record a CAGR of 5.5% from 2025 to 2031.

Executive Summary and North America Human Albumin Market Analysis:

In the US, nearly 35.5 million people are estimated to have chronic kidney disease (CKD). Since CKD leads to hypoalbuminemia, fluid shifts, dialysis-associated volume challenges, and oncotic-support needs, this patient population creates demand for albumin therapeutic interventions. The US mortality from co-occurring cirrhosis and hepatocellular carcinoma increased from 0.68 deaths per 100,000 in 1999 to 1.58 in 2022. As advanced liver disease and cirrhosis cases grow, more patients require large-volume paracentesis, albumin infusions, or plasma-volume support-indications where albumin is guideline-recommended. On the supply and product side, advances in manufacturing and packaging of human albumin preparations (e.g., higher-concentration solutions, improved stabilization) have increased availability in hospital markets and enabled broader indication usage. In Canada, more than 48,375 Canadians were living with end-stage kidney disease (ESKD) in 2022 (with 29,809 on dialysis and 18,566 with a functioning kidney transplant). In North America, the human albumin market is growing due to a rising number of kidney and liver disease patients, increasing use of albumin in critical care, renal replacement, and hepatology, greater recognition of its therapeutic value, and improved access to the product.

North America Human Albumin Market: Strategic Insights

North America Human Albumin Market Segmentation Analysis:

• By Application, the North America Human Albumin Market is segmented into Therapeutic Applications, Drug Delivery, Disease Diagnostics, Research, and Others. The Therapeutic Applications segment dominated the market in 2024.
• By Therapeutic Application, the North America Human Albumin Market is segmented into Liver and Kidney Diseases, Surgery, Hypovolemia and Hypoalbuminemia, and Others. The Hypovolemia and Hypoalbuminemia segment dominated the market in 2024.
• By End User, the North America Human Albumin Market is segmented into Hospitals and Clinics, Pharmaceutical and Biotechnological Companies, Research Institutes, Diagnostic Laboratories, Homecare Settings, and Others. The Hospitals and Clinics segment dominated the market in 2024.

North America Human Albumin Market Players Density: Understanding Its Impact on Business Dynamics

The North America Human Albumin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

North America Human Albumin Market Outlook

In North America, the burden of chronic liver disease continues to rise, driven by increasing prevalence of nonalcoholic fatty liver disease (NAFLD), alcohol-associated liver disease, and viral hepatitis. In the United States, chronic liver disease remains a leading cause of morbidity and mortality, with thousands of hospitalizations annually related to cirrhosis, hepatic decompensation, ascites, and liver failure. These conditions frequently result in hypoalbuminemia and fluid imbalance, creating a significant need for albumin-based volume expansion and supportive care. In response to growing clinical demand, manufacturers are investing in plasma collection networks and expanding fractionation capacity across the region. Regulatory approvals for plasma-derived therapies and improvements in manufacturing technologies are further strengthening product availability. As healthcare providers increasingly adopt guideline-recommended albumin therapy for complications such as spontaneous bacterial peritonitis and hepatorenal syndrome, the demand for human albumin is expected to continue growing, making the increasing burden of liver disease a key driver of the North American albumin market.

North America Human Albumin Market Country Insights

By country, the North America Human Albumin Market is segmented into the United States, Canada, and Mexico. The United States held the largest share in 2024.

CKD frequently leads to hypoalbuminemia and fluid shifts and requires albumin infusions during dialysis or renal replacement therapy. According to a JAMA Open study, the US mortality rate from alcohol associated liver disease doubled from 1999 to 2022 (6.71 to 12.53 deaths per 100,000), signaling increasing decompensated liver disease and ascites, where albumin is guideline-recommended. Clinical guidance in the US, such as the 2023 American Gastroenterological Association expert review, emphasizes that intravenous albumin should be administered in decompensated cirrhosis at large volume paracentesis (> 5L) or in spontaneous bacterial peritonitis/hypovolaemia settings. The US regulatory environment has enabled the introduction of newer albumin products and packaging formats. The ALBUMINEX 5% and 25% solutions from Bio Products Laboratory (THE US launch) and the approval of Kedbumin by the Food and Drug Administration (STN 125384) give more supply and therapeutic options. The high prevalence of kidney and liver disease, aligned clinical guidelines, and product availability drive the growth of the US human albumin market.

North America Human Albumin Market Company Profiles

Some of the key players operating in the market include CSL Ltd, Biotest AG., Octapharma AG, Takeda Pharmaceutical Co Ltd, Merck KGaA, Grifols SA, Taibang Bio Group Co. Ltd., HiMedia Laboratories Pvt Ltd, Thermo Fisher Scientific Inc., and InVitria.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

North America Human Albumin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise